AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01974440
Drug: PCI-32765 (Ibrutinib)
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 560 mg (4\*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.
Trial: NCT00331838
Drug: Placebo (for Semuloparin sodium)
RxNorm normalized name: Semuloparin
DrugBank: Semuloparin (DB06294)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component~Subcutaneous injection
Trial: NCT00254553
Drug: Testim 1% (testosterone gel)
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testim_ 100 mg: two tubes of 50 mg of Testim_per day
Trial: NCT03925662
Drug: Folfox with avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Folfox with avastin only
Trial: NCT03925662
Drug: Mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folfox with avastin with mebendazole
Trial: NCT03214250
Drug: APX005M
RxNorm normalized name: CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M
DrugBank: Sotigalimab (DB16413)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer intravenously once every 28-day Cycle
Trial: NCT03214250
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administer intravenously twice every 28-day cycle
Trial: NCT03214250
Drug: Nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administer intravenously on 3 times every 28-day cycle
Trial: NCT03214250
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administer intravenously 3 times every 28-day cycle
Trial: NCT00508534
Drug: SB-751689
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00727129
Drug: Divigel
RxNorm normalized name: Divigel
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02115282
Drug: Entinostat
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02115282
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02115282
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04189341
Drug: Erector spinae plane block (Group E)
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Trial: NCT02115282
Drug: Goserelin Acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT04189341
Drug: Modified-thoracolumbar interfascial plane block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Trial: NCT00523549
Drug: valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 160 mg or 320 mg tablets once a day
Trial: NCT00523549
Drug: amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg or 10 mg tablets once a day
Trial: NCT01579110
Drug: levamisole
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole 2.5mg/kg(every other day) over six months.~Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
Trial: NCT01207752
Drug: Systane Balance
RxNorm normalized name: Systane Balance
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artificial tear emulsion drop
Trial: NCT05598281
Drug: AMG 510
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT01579110
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
Trial: NCT01219777
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
Trial: NCT01219777
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
Trial: NCT01219777
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 60-80 mg/m2 administered on Day 1, 8 \& 15 during cycle 1-3. Treatment cycle consists of 21 days duration.
Trial: NCT03084939
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
Trial: NCT05598281
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT00613613
Drug: fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate 145mg tablets once daily for 4 weeks
Trial: NCT00087477
Drug: Pivanex
RxNorm normalized name: Pivanex
DrugBank: AN-9 (DB05103)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00162552
Drug: pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with severe cirrhosis treated with Pentoxifylline
Trial: NCT00404508
Drug: Hydralazine and magnesium valproate
RxNorm normalized name: magnesium valproate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02414555
Drug: fluid bolus
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02414555
Drug: Elo-Mel Isoton (balanced acetat-based infusate)
RxNorm normalized name: Mel
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00629551
Drug: saredutant (SR48968)
RxNorm normalized name: Saredutant
DrugBank: Saredutant (DB06660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration,capsules
Trial: NCT00629551
Drug: paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration, capsules
Trial: NCT00557336
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02476058
Drug: JNJ-42847922
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
Trial: NCT02476058
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
Trial: NCT03756922
Drug: FDL169
RxNorm normalized name: FDL169
DrugBank: FDL169 (DB16878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFTR corrector
Trial: NCT03682380
Drug: Seltorexant High Dose
RxNorm normalized name: high-density polyethylene
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 1, Part 2, and Part 3 (3A and 3C), Seltorexant high dose (either a high dose tablet or two low dose tablets) will be administered orally.
Trial: NCT03682380
Drug: Seltorexant Low Dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 3 (3B and 3C), Seltorexant low dose will be administered orally.
Trial: NCT02252172
Drug: Daratumumab IV
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).
Trial: NCT02252172
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.
Trial: NCT02252172
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 40 mg orally or intravenously once in a week.
Trial: NCT02252172
Drug: Daratumumab SC
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study end. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator.
Trial: NCT03693391
Drug: JNJ-64140284
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.
Trial: NCT01744756
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One subconjunctival aplication of Bevacizumabe 0,5ml
Trial: NCT00335374
Drug: Pardoprunox
RxNorm normalized name: Pardoprunox
DrugBank: Pardoprunox (DB12061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 -42 mg
Trial: NCT01476124
Drug: morphine Placebo
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine Placebo
Trial: NCT01476124
Drug: GEn 600 mg
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil 600 mg
Trial: NCT01476124
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine extended release 60 mg
Trial: NCT01381458
Drug: ACs
RxNorm normalized name: EACS
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tiotropium alone, ipratropium alone, or in combination with albuterol
Trial: NCT00402584
Drug: sibutramine
RxNorm normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04300322
Drug: Vaginal Progesterone
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
Trial: NCT00646711
Drug: Depakote ER
RxNorm normalized name: Depakote ER
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
Trial: NCT01717170
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (4 mg/kg or 8 mg/kg)
Trial: NCT02511340
Drug: Flumatinib mesylate tablet 600 mg qd
RxNorm normalized name: eprosartan
DrugBank: Flumatinib (DB11904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients
Trial: NCT00751205
Drug: Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid. Treatment with Sagopilone and ALC will be continued as long as there is benefit. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
Trial: NCT00751205
Drug: Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment will be continued as long as there is benefit. In addition, subjects will receive 21 weeks of placebo 1000 mg tid. After all patients have completed 6 cycles of treatment, an analysis will be performed to see whether ALC was better than placebo. If this is the case, patients still under placebo treatment will be offered to switch to ALC. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
Trial: NCT02201771
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02201771
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01491763
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg p.o. from day 1 until consolidation
Trial: NCT00504413
Drug: midazolam(drug), digoxin (drug)
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midazolam (2mg po) and digoxin (0.5mg po) will be administered one time, an hour apart. Blood concentration will be collected at various points in an 8 hour period.
Trial: NCT00504413
Drug: Bupropion (drug)
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion (150mg po) will be administered one time on a separate visit. Blood concentrations will be collected at various points in a 72 hour period.
Trial: NCT00504413
Drug: Methadone (drug)
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methadone (10mg po) will be administered at a separate visit 2 weeks after the bupropion visit. The dose is given once. Blood concentrations will be measured at various points in a 72 hour period. Pupil constriction will be measured and urine will be collected during this period as well.
Trial: NCT02057289
Drug: Micafungin
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.
Trial: NCT01127217
Drug: amlodipine/losartan
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amlodipine 5mg/losartan 50mg, amlodipine 10mg/losartan 50mg (+HCTZ 12.5mg)
Trial: NCT01344499
Drug: Adept
RxNorm normalized name: ADAPT
DrugBank: Icodextrin (DB00702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: instillation of 1 liter of fluid at the end of laparoscopy
Trial: NCT00238498
Drug: vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT02906696
Drug: Bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00583115
Drug: Gleevec
RxNorm normalized name: Gleevec
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 260 mg/M2/day, given once daily by mouth
Trial: NCT00634920
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (Certican®) tablets administered orally in two divided doses (b.i.d.) at a starting dose of 4 mg/day adjusted to target a trough blood concentration between 6 and 10 ng/mL in period 2.
Trial: NCT00634920
Drug: cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA (Sandimmun Neoral), based on C0-h levels 75-200 ng/mL or C2-h levels 700 900 ng/mL from randomization to Month 6, or C0-h levels 50-150 ng/mL or C2-h levels 600 800 ng/mL from Month 6 to Month 36, according to local method
Trial: NCT00634920
Drug: Basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
Trial: NCT02101268
Drug: Momelotinib
RxNorm normalized name: MOMELOTINIB
DrugBank: Momelotinib (DB11763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Momelotinib tablet administered orally once daily
Trial: NCT01127217
Drug: amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amlodipine 5mg, amlodipine 10mg (+ HCTZ 12.5mg)
Trial: NCT04358068
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02625753
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
Trial: NCT00237211
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01193218
Drug: BI 10773
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 10773 tablets low dose once a day
Trial: NCT01193218
Drug: BI 10773
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 10773 tablets mid-high dose once a day
Trial: NCT01193218
Drug: BI 10773
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 10773 tablets high dose once a day
Trial: NCT01193218
Drug: BI 10773
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 10773 tablets mid-low dose once a day
Trial: NCT02094794
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00548002
Drug: trovafloxacin and levofloxacin
DrugBank: Trovafloxacin (DB00685)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trovafloxacin: \<60 kg 200 mg iv/orally once daily and \>60 kg 300 mg iv/orally once daily Levofloxacin: \< 60 kg 500 mg iv/orally once daily and \>60 kg 500 mg iv/orally bid
Trial: NCT00238719
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002597
Drug: flutamide
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two 125 mg capsules (t.i.d., p.o.) beginning two months before RT and continuing until RT is completed.
Trial: NCT00002597
Drug: Zoladex
RxNorm normalized name: Zoladex
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3.6 mg s.c. monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
Trial: NCT00002597
Drug: Lupron
RxNorm normalized name: Lupron
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg IM (intramuscular) monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
Trial: NCT04785716
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib provided through the patient access program
Trial: NCT03046381
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 162mg 1x weekly s.c.
Trial: NCT04114097
Drug: Betnovate, betamethasone dipropionate ointment 0.1% and placebo
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Explore the systemic effects of Betnovate
Trial: NCT04114097
Drug: Protopic, tacrolimus ointment 0.1%
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compare the systemic effects of Betnovate to Protopic
Trial: NCT01677949
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Days 1-5: Clofarabine 30 mg/m\^2 for 0-30 years of age or 20 mg/m\^2 for \> 30 years of age intravenously (IV) over 2 hours